Harmony Biosciences Holdings, INC Form 4 insider transactions

Director Geno J. Germano was granted 21,231 stock options in Harmony Biosciences Holdings, Inc. as part of standard compensation.

Harmony Biosciences Holdings, Inc. reports that Director Linda M. Szyper acquired stock options on May 14, 2026, as detailed in a Form 4 filing.

Harmony Biosciences Holdings, Inc. reports that Director Philip Ron M acquired stock options on May 14, 2026.

Harmony Biosciences Holdings, Inc. Director Mark Graf acquired stock options, as disclosed in a Form 4 filing.

Harmony Biosciences Holdings, Inc. Director Juan A. Sabater acquired 21,872 stock options with an exercise price of $30.76, vesting under specific service conditions.

Harmony Biosciences Holdings, Inc. reports a Form 4 filing detailing changes in beneficial ownership for Chief Medical Officer Kumar Budur, including stock withholding and RSUs.

Harmony Biosciences Holdings, Inc. reports that Chief Financial Officer Glenn Reicin acquired stock options.

Harmony Biosciences Holdings, Inc. reports insider transactions involving Chief Commercial Officer Adam H. Zaeske, including the acquisition of restricted stock units and the disposal of shares.

Harmony Biosciences Holdings, Inc. reports a significant stock option grant to Chief Operating Officer Peter Anastasiou.

Harmony Biosciences Holdings, Inc. reports that Director Troy A. Ignelzi acquired stock options on April 2, 2026, as detailed in a Form 4 filing.

Harmony Biosciences' Chief Financial Officer, Sandip Kapadia, sold 3,746 shares of common stock for a weighted average price of $37.152 per share as part of a pre-arranged trading plan.

Harmony Biosciences' Chief Financial Officer, Sandip Kapadia, reported new equity grants and the vesting of previously awarded restricted stock units, along with shares withheld for tax obligations.

Harmony Biosciences' Chief Strategy Officer, Andrew Serafin, reported the acquisition of new stock options and restricted stock units, alongside the vesting and tax-related disposition of previously granted equity.

Harmony Biosciences' Chief Medical Officer, Dr. Budur Kumar, reported recent equity transactions including new stock option and RSU grants, alongside the vesting and tax-related disposition of previously awarded restricted stock units.

Harmony Biosciences' Chief Commercial Officer, Adam H. Zaeske, received significant equity awards, including stock options and restricted stock units, tied to future service.

Harmony Biosciences CEO Jeffrey M. Dayno reported significant equity transactions, including new stock option and RSU grants, and the vesting and tax-related disposition of previously granted RSUs.

Harmony Biosciences Chief Financial Officer Sandip Kapadia sold 20,961 shares of common stock for a weighted average price of $35.9159 per share through a pre-arranged Rule 10b5-1 trading plan.

Harmony Biosciences Holdings, Inc. President and CEO, Jeffrey M. Dayno, exercised stock options and subsequently sold a portion of the acquired common stock under a Rule 10b5-1 trading plan.

Harmony Biosciences' Chief Financial Officer, Sandip Kapadia, exercised stock options and subsequently sold 20,000 shares of common stock under a Rule 10b5-1 trading plan.

Harmony Biosciences CFO Sandip Kapadia sold 3,427 shares of common stock for $35 per share under a Rule 10b5-1 plan.

Harmony Biosciences CFO Sandip Kapadia reported the vesting of 45,000 restricted stock units and the subsequent withholding of 24,039 shares for tax obligations.

Valor IV Pharma Holdings, LLC has completed an in-kind pro rata distribution of 6.6 million Harmony Biosciences common shares to its underlying entities and individuals.

Harmony Biosciences CFO Sandip Kapadia sold 21,573 shares of common stock for approximately $787,470 under a pre-arranged trading plan.

Director Juan A. Sabater acquires stock options in Harmony Biosciences Holdings, Inc.

Director Antonio J. Gracias acquired 14,522 stock options in Harmony Biosciences Holdings, Inc. on May 15, 2025.

Director Ron M. Philip acquires 14,522 stock options in Harmony Biosciences Holdings, Inc.

Director Linda Szyper acquired 14,522 stock options in Harmony Biosciences Holdings, Inc. on May 15, 2025.

Director Peter Anastasiou of Harmony Biosciences Holdings, Inc. received stock options on May 15, 2025.

Director R. Mark Graf acquired 14,522 stock options in Harmony Biosciences Holdings, Inc.

Director Gary Sender acquired 14,522 stock options in Harmony Biosciences Holdings, Inc. on May 15, 2025.